Scientists Develop New HIV Treatment That Pushes Virus to Undetectable Levels

Scientists are reporting encouraging progress in the fight against HIV/AIDS after an experimental immune-cell therapy helped two patients suppress the virus to undetectable levels following a single treatment.

The early-stage research, which is set to be presented at a gene therapy conference in Boston, offers fresh hope that long-term control of HIV may one day be possible without the need for daily medication.

While the treatment is still in its early stages and remains far from widespread clinical use, researchers say the findings represent an important proof of concept for future HIV therapies. The experimental approach borrows from a strategy already used successfully in certain blood cancer treatments.

For years, scientists have treated some cancers by collecting a patient’s own immune cells, genetically modifying them to identify and attack cancerous cells, and then infusing them back into the body.

Researchers are now adapting that same concept to target HIV. In the new study, scientists engineered patients’ immune cells to specifically recognize and attack cells infected with HIV.

Following a single infusion of these modified immune cells, two participants in the trial successfully reduced their viral levels to undetectable amounts.

According to researchers, one of the patients has maintained this suppression for nearly two years. This is particularly significant because HIV is known for its ability to hide within the body, evade immune responses, and establish long-term reservoirs that make complete eradication extremely difficult.

Current HIV treatment typically requires lifelong antiretroviral therapy to keep the virus under control. Although these medications are highly effective, they do not eliminate HIV from the body and must be taken consistently.

The new therapy raises the possibility that future treatments could reduce or potentially eliminate the need for continuous medication by enabling the immune system to better control the virus independently.

Leading the study is Steve Deeks, an HIV expert at the University of California, San Francisco. Deeks described the results as an important source of inspiration and a possible roadmap for future progress in HIV research.

According to him, while the treatment is still years—if not decades—away from becoming broadly accessible, the study demonstrates that this therapeutic direction is scientifically plausible. The findings were reportedly shared in advance with The New York Times ahead of the official conference presentation.

Researchers caution that the study involved only a small number of participants, meaning far more testing is required before drawing broader conclusions about effectiveness, durability, and safety.

Still, the results have generated optimism within the medical and scientific community. For decades, scientists have searched for ways to achieve either a complete HIV cure or what is known as a “functional cure,” where the virus remains controlled without ongoing treatment.

This latest breakthrough may represent another meaningful step toward that long-term goal. Although not yet a cure, the study strengthens hopes that advances in gene therapy and immune engineering could eventually transform HIV from a lifelong condition requiring daily treatment into one managed with far less medical intervention.